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Abstract
AIM: To evaluate the prognostic value of electrophy-
siological stimulation (EPS) in the risk stratification for 
tachyarrhythmic events and sudden cardiac death (SCD).
METHODS: We conducted a prospective cohort 
study and analyzed the long-term follow-up of 265 
consecutive patients who underwent programmed 
ventricular stimulation at the Luzerner Kantonsspital 
(Lucerne, Switzerland) between October 2003 and April 
2012. Patients underwent EPS for SCD risk evaluation 
because of structural or functional heart disease and/or 
electrical conduction abnormality and/or after syncope/
cardiac arrest. EPS was considered abnormal, if a 
sustained ventricular tachycardia (VT) was inducible. 
The primary endpoint of the study was SCD or, in 
implanted patients, adequate ICD-activation.
RESULTS: During EPS, sustained VT was induced 
in 125 patients (47.2%) and non-sustained VT in 60 
patients (22.6%); in 80 patients (30.2%) no arrhythmia 
could be induced. In our cohort, 153 patients (57.7%) 
underwent ICD implantation after the EPS. During 
follow-up (mean duration 4.8 ± 2.3 years), a primary 
endpoint event occurred in 49 patients (18.5%). 
The area under the receiver operating characteristic 
curve (AUROC) was 0.593 (95%CI: 0.515-0.670) for 
a left ventricular ejection fraction (LVEF) < 35% and 
0.636 (95%CI: 0.563-0.709) for inducible sustained 
VT during EPS. The AUROC of EPS was higher in 
the subgroup of patients with LVEF ≥ 35% (0.681, 
95%CI: 0.578-0.785). Cox regression analysis showed 
that both, sustained VT during EPS (HR: 2.26, 95%CI: 
1.22-4.19, P  = 0.009) and LVEF < 35% (HR: 2.00, 
95%CI: 1.13-3.54, P  = 0.018) were independent 
predictors of primary endpoint events.
CONCLUSION: EPS provides a benefit in risk stratification 
Prospective Study
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for future tachyarrhythmic events and SCD and should 
especially be considered in patients with LVEF ≥ 35%.
Key words: Electrophysiologic techniques; Cardiac; 
Arrhythmia; Cardiac; Sudden cardiac death
© The Author(s) 2015. Published by Baishideng Publishing 
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Core tip: In our long-term prospective cohort study 
we could reveal several important findings about 
the prognostic value of programmed ventricular 
stimulation for risk stratification of sudden cardiac 
death (SCD). First, in a mixed population with different 
cardiac pathologies inducible sustained ventricular 
tachyarrhythmia during electrophysiological stimulation 
(EPS) identified those at higher risk for SCD or 
appropriate implantable cardioverter defibrillators (ICD) 
activation. Second, left ventricular ejection fraction 
(LVEF) < 35% was another independent predictor of 
SCD surrogate. Third, in patients with LVEF > 35% 
negative EPS had a high negative predictive value for 
SCD and ICD activation.
Hilfiker G, Schoenenberger AW, Erne P, Kobza R. Utility of 
electrophysiological studies to predict arrhythmic events. World J 
Cardiol 2015; 7(6): 344-350  Available from: URL: http://www.
wjgnet.com/1949-8462/full/v7/i6/344.htm  DOI: http://dx.doi.
org/10.4330/wjc.v7.i6.344
INTRODUCTION
Implantable cardioverter defibrillators (ICD) are 
an established therapy for primary and secondary 
sudden cardiac death (SCD) prevention. Randomized 
trials have shown a significant mortality reduction in 
implanted patients at high risk for SCD[1-4]. For ICD 
therapy guidance, evaluation of SCD risk is crucial. 
Guidelines recommend various non-invasive techniques 
to recognize patients at higher risk for life-threatening 
arrhythmias[5]. Factors associated with a significantly 
increased risk of ventricular tachyarrhythmia include 
increased resting heart rate, wide QRS, presence of 
late potentials, presence of heart failure, or lower left 
ventricular ejection fraction[6-10]. However, currently 
available methods for SCD risk estimation are still 
imprecise. Therefore, many patients, who received an 
ICD, are not going to suffer from a future arrhythmic 
event and do not benefit from ICD. On the other hand, 
many patients, who are not recognized at high risk, die 
from SCD and numbers of SCD victims are still highest 
in these patients with normal left ventricular ejection 
fraction (LVEF)[11,12]. It remains an ongoing challenge 
to predict an individual patient’s risk.
Currently, the electrophysiological study (EPS) 
is widely used for risk stratification and several 
randomized trials suggest a significant predictive value 
of this examination. However, many previous studies 
focused on the predictive value in one subgroup of 
patients with a specific cardiac pathology. Most data 
are available from post myocardial infarction patients 
in whom inducible ventricular tachycardias (VT) or 
ventricular fibrillation (VF) during EPS indicate higher 
risk for future arrhythmic events[13]. An improved 
risk stratification with EPS has especially been shown 
in patients who were preselected as a high risk 
population based on previous non-invasive tests[14,15]. 
Other studies provided a prognostic value of EPS in 
patients with Brugada syndrome, hypertrophic or 
dilated cardiomyopathy[16-18]. The discussion about the 
general prognostic value of electrophysiological testing 
is ongoing. We therefore performed an induction study 
of VT or VF by programmed electrical stimulation either 
for primary prevention of SCD, after documented VT 
or in SCD survivors. The usefulness of EPS for the 
prediction of future arrhythmic events was evaluated 
in a prospective long-term follow-up in patients with 
different cardiac pathologies.
MATERIALS AND METHODS
Study population
This prospective cohort study evaluated all patients 
who were examined by EPS at the Luzerner Kan-
tonsspital (Lucerne, Switzerland) between October 
2003 and April 2012. Patients underwent EPS for SCD 
risk evaluation because of structural or functional 
heart disease and/or electrical conduction abnormality 
and/or after syncope/cardiac arrest. The study popu-
lation therefore embraced patients with coronary 
artery disease (CAD), dilated cardiomyopathy (DCM), 
hypertrophic cardiomyopathy, impaired LVEF, Brugada 
or Long QT syndrome, and other rare cardiac diseases 
(e.g., valvular heart disease, tetralogy of Fallot, variant 
angina). Some patients who underwent EPS did not 
have cardiac disease but were assessed because of 
unclear syncope or family history of cardiomyopathy. 
Patients who did not provide written informed 
consent were excluded. The study complies with the 
Declaration of Helsinki and was approved by the local 
ethics committee.
Baseline evaluation
All participating patients were evaluated at baseline. 
Patient history was recorded including cardiovascular 
risk factors, underlying heart disease, and medication. 
Electrocardiogram (ECG) was recorded in all patients. 
LVEF was measured with transthoracic echocardiography 
in all patients and was determined on two- and four-
chamber views using the modified biplane Simpson 
method.
EPS was part of the baseline evaluation and was 
performed according to the ACC/AHA/ESC guidelines for 
the management of patients with ventricular arrhythmias 
and the prevention of sudden cardiac death[19]. The 
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ventricular arrhythmia induction protocol during EPS 
included programmed stimulation at three basic cycle 
lengths (600, 450, and 350 ms) and up to three 
extrastimuli with a minimum coupling interval of 180 
ms. A third extrastimulus was introduced during a basic 
drive cycle length of minimal 500 ms after completion 
of programmed ventricular stimulation with 1 and 2 
extrastimuli during paced cycle lengths of 600, 450, and 
350 ms[20]. EPS was considered abnormal, if a sustained 
VT was inducible.
Follow-up
Patients with ICD were regularly followed-up at 
Luzerner Kantonsspital in six-month or yearly intervals. 
In addition, they were followed-up immediately, if 
shocks occurred. The clinical course and the numbers 
of appropriate and inappropriate ICD therapies were 
protocoled at each follow-up visit. In patients who had 
no ICD, follow-up was obtained from several sources: 
first, medical records at Luzerner Kantonsspital were 
studied, if available (i.e., in patients who were re-
admitted after the EPS); second, the patients and/or 
their general practitioner were contacted by phone and 
interviewed using a structured protocol. In all patients 
who died, additional information on the circumstances 
of death was collected. Death was classified as non-
cardiac or cardiac. Among cardiac deaths, SCD was 
defined according to the Hinkle-Thaler method[21].
Endpoints
The primary endpoint of this study was SCD or, in 
implanted patients, adequate ICD activation [shock or 
antitachycardia pacing (ATP)]. The secondary endpoint 
was SCD or adequate ICD shock. For the secondary 
endpoint, events with ATP were not counted. If a 
patient experienced more than one endpoint event 
(e.g., ICD shock in a patient who later died from SCD), 
only the first endpoint event was counted.
Statistical analysis
We descriptively analyzed baseline characteristics. We 
then calculated sensitivity, specificity, positive predictive 
value (PPV), negative predictive value (NPV), and the 
area under the receiver operating characteristic curve 
(AUROC) with its 95%CI of the EPS for the prediction 
of both endpoints[22]. The diagnostic accuracy of 
the EPS was compared to that of the LVEF. For this 
purpose, LVEF was dichotomized at 35% (< 35% 
indicating higher risk vs ≥ 35% indicating lower risk). 
We also performed a Cox regression analysis with age, 
sex, EPS and LVEF as independent variables. Kaplan-
Meier survivor functions were generated to illustrate 
the ability to stratify the risk of both dichotomized 
predictors separately[23]. Calculations were done for 
all study participants together and, in a sensitivity 
analysis, repeated separate for participants with 
CAD and DCM. Data were analyzed using Stata 11.2 
(StataCorp LP, College Station, TX, United States).
RESULTS
Study population
Overall, 289 patients underwent EPS during the 
study period. Twenty-four patients (8.3%) were 
lost to follow-up, resulting in 265 patients who were 
analyzed. Table 1 shows the baseline characteristics of 
study participants. Mean age was 57.4 ± 10.7 years 
with a maximum range from 21.8 to 76.7 years. Most 
participants were male. CAD was present in a majority 
of patients.
EPS and therapeutic consequences
The EPS was performed for primary prevention in 
209 patients (78.9%). In 56 patients (21.1%) the 
indication was secondary prevention: twenty-nine 
cardiac arrest survivors (10.9%), and 27 patients 
(10.2%) who had documented VT/VF on previous 
ECGs. During EPS, sustained VT was induced in 125 
patients (47.2%) and non-sustained VT in 60 patients 
(22.6%). In 80 patients (30.2%) no arrhythmia could 
be induced.
In our cohort, 153 patients (57.7%) underwent 
ICD implantation after the EPS, and 112 patients 
(42.3%) received no ICD. Patients were selected for 
device implantation according to the specific ACC/
AHA/ESC guidelines for the underlying heart disease. 
The decision to implant an ICD was influenced by the 
result of the EPS if recommended in the guidelines. 
Antiarrhythmic medication consisted of beta blockers 
in 214 patients (80.8%), amiodarone in 38 patients 
(14.3%), and digoxin in 37 patients (14.0%).
Follow-up and endpoint events
The mean duration of the follow-up was 4.8 ± 2.3 
years (interquartile range 3.1-6.2 years, maximum 
range 0.2-9.2 years). During follow-up, 28 patients 
(10.6%) died, 12 of them due to non-cardiac causes. 
Among the 16 patients with a cardiac cause of death, 
SCD occurred in 8 patients. A primary endpoint event 
occurred in 49 patients (18.5%) with a mean time 
interval since the EPS of 947 ± 778 d (maximum range 
16-3050 d). Table 1 shows baseline characteristics 
separate for patients with and without primary 
endpoint event. There were no significant differences 
between the two groups, except for LVEF which was 
lower in patients with primary endpoint event, and the 
findings during EPS that found more sustained VTs 
in patients with primary endpoint event. A secondary 
endpoint event occurred in 33 patients (12.5%) with 
a mean time interval since the EPS of 997 ± 761 d 
(maximum range 63-2709 d).
Diagnostic accuracy
Table 2 shows the diagnostic accuracy of the EPS and 
the LVEF for primary and secondary endpoint. The 
AUROCs of EPS and of LVEF did not significantly differ 
(P = 0.427 for primary endpoint, and P = 0.676 for 
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Sensitivity analysis
Main analysis were repeated separate for participants 
with CAD and DCM. Among the 152 CAD patients, a 
primary endpoint event occurred in 32 patients (21.1%). 
The AUROCs of the EPS (0.604, 95%CI: 0.516-0.693) 
and of LVEF (0.606, 95%CI: 0.509-0.704) were similar 
to the overall study population and did not significantly 
differ (P = 0.975). Among the 58 patients with DCM, 
a primary endpoint event occurred in 13 patients 
(22.4%). Due to the low numbers of patients, the 
AUROC of the EPS (0.625, 95%CI: 0.469-0.781) had 
a broad 95%CI. The AUROC of LVEF (0.425, 95%CI: 
secondary endpoint). There was a non-significant 
trend for a higher AUROC of the EPS in the subgroup 
of patients with an LVEF ≥ 35% as compared to the 
subgroup of patients with LVEF < 35% (P = 0.156 
for primary endpoint, and P = 0.113 for secondary 
endpoint). Cox regression analysis showed that both, 
sustained VT during EPS (HR: 2.26, 95%CI: 1.22-4.19, 
P = 0.009) and LVEF < 35% (HR: 2.00, 95%CI: 
1.13-3.54, P = 0.018) were independent predictors 
of primary endpoint events. Kaplan-Meier survivor 
functions of EPS and LVEF for the primary endpoint are 
shown in Figure 1.
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Table 2  Diagnostic accuracy of the electrophysiological study and the left ventricular ejection fraction for the primary and 
secondary endpoint
Predictor variable Sensitivity Specificity PPV NPV AUROC (95%CI)
Primary endpoint
Sustained VT during EPS
   All study participants (n = 265) 69.4% 57.9% 27.2% 89.3% 0.636 (0.563-0.709)
   Subgroup of study participants with LVEF < 35% (n = 106) 66.7% 48.1% 30.5% 80.9% 0.574 (0.468-0.680)
   Subgroup of study participants with LVEF ≥ 35% (n = 159) 72.7% 63.5% 24.2% 93.5% 0.681 (0.578-0.785)
LVEF < 35% 55.1% 63.4% 25.5% 86.1% 0.593 (0.515-0.670)
Secondary endpoint
Sustained VT during EPS
   All study participants (n = 265) 66.7% 55.6% 17.6% 92.1% 0.611 (0.524-0.699)
   Subgroup of study participants with LVEF < 35% (n = 106) 61.1% 45.5% 18.6% 85.1% 0.533 (0.406-0.660)
   Subgroup of study participants with LVEF ≥ 35% (n = 159) 73.3% 61.8% 16.7% 95.7% 0.676 (0.553-0.798)
LVEF < 35% 54.5% 62.1% 17.0% 90.6% 0.583 (0.491-0.675)
AUROC: Area under the receiver operating characteristic curve; EPS: Electrophysiological study; NPV: Negative predictive value; PPV: Positive predictive 
value; VT: Ventricular tachycardia; LVEF: Left ventricular ejection fraction.
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Table 1  Baseline characteristics
Characteristic All study participants  
n  = 265
Participants without primary 
endpoint event1 n  = 216
Participants with primary endpoint event1 
n  = 49
P value2
Age, mean ± SD, yr 57.4 ± 10.7 57.5 ± 10.6 57.2 ± 11.3 0.848
Male sex 230 (86.8%) 185 (85.6%) 45 (91.8%) 0.350
Cardiovascular risk factors
Hypertension 152 (57.4%) 124 (57.4%) 28 (57.1%) 0.973
Dyslipidemia 161 (60.8%) 131 (60.6%) 30 (61.2%) 0.941
Diabetes mellitus   60 (22.6%)   49 (22.7%) 11 (22.4%) 0.972
Smoking3 154 (58.1%) 121 (56.0%) 33 (67.3%) 0.147
Family history of CAD   81 (30.6%)   65 (30.1%) 16 (32.7%) 0.725
Cardiac disease
CAD 152 (57.4%) 120 (55.6%) 32 (65.3%) 0.213
DCM   58 (21.9%)   45 (20.8%) 13 (26.5%) 0.384
HCM
Obstructive
Non-obstructive
1 (0.4%)
3 (1.1%)
1 (0.5%)
2 (0.9%)
0 (0.0%)
1 (2.0%)
1.000
0.460
Brugada syndrome 2 (0.8%) 2 (0.9%) 0 (0.0%) 1.000
Long QT 3 (1.1%) 3 (1.4%) 0 (0.0%) 1.000
Other cardiac disease 30 (11.3%) 26 (12.0%) 4 (8.2%) 0.618
Echocardiography
LVEF, mean ± SD 41.1% ± 15.9% 42.8% ± 16.2% 33.6% ± 11.7% < 0.001
LVEF < 35% 106 (40.0%) 79 (36.6%) 27 (55.1%) 0.017
EPS
Induction of sustained VT 125 (47.2%) 91 (42.1%) 34 (69.4%) 0.001
Induction of non-sustained VT   60 (22.6%) 53 (24.5%)   7 (14.3%) 0.122
No VT induction   80 (30.2%) 72 (33.3%)   8 (16.3%) 0.019
1Event of primary endpoint (sudden cardiac death, ICD shock or ATP); 2P value for the comparison of participants without vs with endpoint event; 3Current 
or former smoker. CAD: Coronary artery disease; DCM: Dilated cardiomyopathy; EPS: Electrophysiological study; HCM: Hypertrophic cardiomyopathy; 
LVEF: Left ventricular ejection fraction; SD: Standard deviation; VT: Ventricular tachycardia.
0.268-0.582) was low (P = 0.105 as compared to the 
AUROC of the EPS).
DISCUSSION
This long-term prospective cohort study revealed 
several important findings. First, in a mixed population 
with different cardiac pathologies inducible sustained 
ventricular tachyarrhythmia during EPS identified 
those at higher risk for a SCD surrogate, defined either 
as appropriate ICD activations and/or as documented 
SCD. Second, LVEF < 35% was another independent 
predictor of primary endpoint events. Third, in patients 
with LVEF > 35% negative EPS had a high negative 
predictive value for the primary and for the secondary 
endpoint.
Electrophysiologic testing of ventricular tachycardia 
was introduced 1972[24]. Amongst others, programmed 
ventricular stimulation was used to assess the efficacy 
of antiarrhythmic drugs for suppression of inducible 
ventricular arrhythmias or the efficacy of antitachycardia 
surgery[25]. With the availability of ICDs EPS has become 
an important test for risk stratification to predict SCD[19]. 
The prognostic value of EPS is based on the assumption 
that patients with inducible ventricular tachyarrhythmias 
should have a high likelihood of spontaneous arrhythmic 
events and that non-inducible patients should be at 
low risk[26]. In the current guidelines electrophysiologic 
testing has a class Ⅰ recommendation for diagnostic 
evaluation of patient with remote myocardial infaction 
with symptoms suggestive of ventricular arrhythmias, 
including palpitations, presyncope and syncope. 
Another class Ⅰ indication is syncope of unkown cause 
with impaired LV function or structural heart disease[19]. 
In nonischemic DCM electrophysiologic testing is not 
recommended for risk stratificiation. However, in a 
recent study of Gatzoulis et al[18] inducibility of VT/VF 
in patients with idiopathic dilated cardiomyopathy was 
associated with an increased likelihood of subsequent 
ICD activation and SCD surrogate. In the present study 
we have shown, that EPS is useful for the prediction 
of future arrhythmic events in a collective of patients 
with different cardiac pathologies. It is well established 
that the predictive accuracy of LVEF for lifethreatening 
arrhythmic events is limited[26]. However ICD-Implan-
tation guided by LVEF alone lacks of specificity because 
in progressive heart failure unexpected SCD accounted 
for only 30% of deaths while many were due to 
progressive pump failure not preventable by an ICD.
According to our findings, the additional use of 
electrophysiologic testing in patients with LVEF < 
35% is disputable as the PPV is only improved from 
25.5% to 30.5% in cases with a positive EPS. This 
might not influence the further clinical management 
of the patient because a 25.5% risk of a future 
tachyarrhythmic event or SCD already seems to justify 
ICD implantation. However in patients with LVEF > 
35% and a negative EPS the NPV was improved from 
86.1% to 93.5%. This means that the risk estimation 
for future arrhythmic events during the follow-up 
period of 4.8 ± 2.3 years is reduced from 13.9% to 
6.5%. In addition a positive EPS still exhibits a PPV of 
24.2% in patients with LVEF > 35%.
Similar results were found in the MUSTT trial[27]. 
Both, low ejection fraction and inducible sustained 
ventricular tachycardia during EPS, identified patients 
at increased mortality risk. Inducible tachyarrhythmias 
identified patients for whom death was significantly 
more likely to be arrhythmic and this was observed 
especially if ejection fraction was higher than or equal 
to 30%. Due to our findings, invasive testing should 
especially be considered in this group of higher to 
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Electrophysiological study
Figure 1  Kaplan-Meier function of primary endpoint event-free survival for patients with or without sustained ventricular tachycardia during the 
electrophysiological study and for patients with left ventricular ejection fraction < 35% vs ≥ 35%. VT: Ventricular tachycardia; LVEF: Left ventricular ejection 
fraction.
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normal LVEF, as it might prevent implantation of ICD in 
patient who won’t benefit.
This study has some limitations. First, the findings 
of this study are from a single center. Therefore, 
generalizability is limited and confirmation in an 
independent sample is of importance. Second, we 
included patients who underwent EPS for primary 
prevention as well as for secondary prevention. NPV 
and PPV of sustained ventricular tachycardia during 
EPS might differ in these subgroups, however the study 
population is too small to perform an independent 
statistical analysis.
EPS provides a benefit in risk stratification for 
future tachyarrhythmic events and SCD and should 
especially be considered in patients with LVEF > 35%.
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